A “new” Beovu drug label which was revised in December 2021 sets forth some additional information about the vision-related Beovu side effects intraocular inflammation, retinal vasculitis, and retinal vascular occlusion. We point out, however, that there was no similar 2021 Beovu label change issued by Novartis in the US.
From this Drug Safety Update, “Brolucizumab (Beovu▼): risk of intraocular inflammation and retinal vascular occlusion increased with short dosing intervals”, issued January 18, 2022, by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), we get the following:
New information on [the Beovu adverse events retinal vasculitis and retinal vascular occlusion], including risk factors and possible mechanism, was considered in a recent European safety review and ophthalmologists were informed of the new recommendations in a letter in November 2021. The product information of [Beovu (brolucizumab)] will also be updated to reflect this information.
In the so-called “Dear Doctor” letter about Beovu that Novartis UK sent on November 2, 2021, to healthcare professionals in the UK there are these two important sections:
- “Risk factors identified”; and,
- “Immune‐mediated event”.
We expect that a similar Beovu drug label change, and a possible associated Beovu “Dear Doctor” letter, will be issued by Novartis here in the US soon.
Be assured we will continue to monitor the drug safety regulatory sector for further developments regarding Beovu vision loss side effects such as intraocular inflammation, retinal vasculitis, and retinal vascular occlusion.
For more information about Beovu causing vision loss and blindness due to occlusive retinal vasculitis, retinal artery occlusion, and intraocular inflammation, see our Beovu Side Effects page on our DrugInjuryLaw.com website.
[Read article in full at original source]